Significant changes have been introduced with the release of ISO 1856:2024, impacting testing strategies, risk assessments, and even regulatory compliance. Join Eurofins experts to learn critical insights into how these changes impact regulatory strategy and current devices, including regulatory implications for FDA submissions not completed by the July 5, 2026 deadline.

During this webinar you will learn:

• A comprehensive overview of ISO 18562:2024 testing requirements
• Inclusion of personal protective equipment (PPE) within the standard’s expanded scope
• New testing requirements, including evaluation of aldehydes and very volatile organic compounds (VVOCs)
• The importance of lifecycle management and post-market surveillance
• Alignment of ISO 18562-4 with ISO 10993

Andrew Blakinger Senior Manager Eurofins Medical Device Services

As Senior Manager, Andrew Blakinger leads the Chemistry and Extractables & Leachables Testing team for Eurofins Medical Device Services. He has more than 13 years of experience planning, managing, and conducting E&L studies for medical devices and delivery systems as well as pharmaceutical container closure systems and manufacturing equipment. Additionally, he previously oversaw Eurofins’ container closure integrity testing (CCIT) and compendial container testing team as well as their team in toxicological services.. He holds vast expertise and experience in ICP-OES testing and analysis by LC/MS. Andrew earned a B.A. in chemistry from Clemson University.